Brief: Merus NV says MCLA-129 Observed To Be Well Tolerated With A Favorable Safety Profile

Merus NV

26/10/2022 09:03

Oct 26 (Reuters) - Merus NV  MRUS.O :
    * MERUS PRESENTS FIRST IN HUMAN DATA ON MCLA-129 AT THE 34TH
EORTC/NCI/AACR (ENA) SYMPOSIUM ON MOLECULAR TARGETS AND CANCER
THERAPEUTICS
    * MCLA-129 OBSERVED TO BE WELL TOLERATED WITH A FAVORABLE
SAFETY
PROFILE
    * ANTITUMOR ACTIVITY WAS OBSERVED AMONG HEAVILY PRETREATED
PATIENTS, ACROSS MULTIPLE TUMOR TYPES AND DOSE LEVELS
    * INITIAL RECOMMENDED PHASE 2 DOSE 1500 MG EVERY TWO WEEKS;
EXPANSION COHORTS ENROLLING

Source text for Eikon:  ID:nGNXbtNXzc 
Further company coverage:  MRUS.O 
 ((Reuters.Brief@thomsonreuters.com;))